The National Ambulatory Medical Care Survey (NAMCS) provides valuable insights into real-world prescribing patterns of GLP-1 agonists and their associations with obesity and cardiovascular risk factors in US adults with T2DM [19]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.